BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» Unauthorized FDCs in cross-hairs of India's CDSCO
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Unauthorized FDCs in cross-hairs of India's CDSCO
April 18, 2018
By
T.V. Padma
No Comments
NEW DELHI – India's drug quality administration is cracking down on companies that manufacture and sell unauthorized and untested fixed-dose combination (FDC) drugs, following recent inspections that brought that issue into the spotlight.
BioWorld Asia